GLPwatch
Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations.
Front Endocrinol (Lausanne) · 2021
Last updated 2026-05-28| Journal | Front Endocrinol (Lausanne), 2021 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.23 |
| NIH percentile | 15 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Chronic Kidney Disease |
Full record and abstract on PubMed 34630338 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.